Top Story

Analysis: Most patients prescribed Qsymia as intended

May 22, 2015

NASHVILLE, Tenn. - Adults assigned the weight-loss drug Qsymia are mostly women and white, with a large percentage also taking medications for diabetes and hypertension, according to study findings presented here.

In a prospective, pharmacoepidemiologic database study, researchers analyzed electronic data of patients prescribed Qsymia (phentermine/topiramate extended-release capsules, Vivus), a weight-loss drug intended for patients with a BMI of at least 30 kg/m2, and concluded that the drug is being prescribed as intended.

In the Journals

Caffeine consumption reduces risk of erectile dysfunction

May 22, 2015
Men who consumed between 85 mg and 303 mg of caffeine per day were less likely to experience erectile dysfunction, compared with men who consumed less than 7 milligrams…
Meeting News Coverage

Clinical characteristics, hospital outcomes differ between type 1, type 2 diabetes

May 22, 2015
NASHVILLE, Tenn. - Age-matched patients with type 1 and type 2 diabetes reveal significant differences in inpatient clinical characteristics and hospital outcomes…
VIDEO: New osteoporosis guidelines for menopausal women to be released later this year Meeting News CoverageVideo

VIDEO: New osteoporosis guidelines for menopausal women to be released later this year

May 21, 2015
NASHVILLE, Tenn. — Pauline Camacho, MD, FACE, president elect of AACE, discusses the upcoming guidelines for postmenopausal women expected to be released later…
Howard Wolpert, MD Cover StoryPublication Exclusive

Continuous glucose monitoring poised to revolutionize day-to-day diabetes management

Endocrine Today, May 2015
Diabetes has become a global epidemic. Currently, 387 million people worldwide have diabetes; that number is expected to swell to 582 million by 2035, according to the…
More News Headlines »
CME
Assessing Cornerstones for Successful Weight Loss

Assessing Cornerstones for Successful Weight Loss: Building a Foundation that Really Works

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc.

Obesity has increased dramatically in the past 2 decades and is now considered a health care epidemic in the United…
More »
Meeting News Coverage Video
VIDEO: Year in Pituitary Disease examines new developments

VIDEO: Year in Pituitary Disease examines new developments

May 20, 2015
NASHVILLE, Tenn. — In this video exclusive, Mark Molitch, MD, discusses a number of new developments in…
More »
CME
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Current Issues
View the Current Issues